Virally-induced tumorigenesis controlled by the microbiota
由微生物群控制的病毒诱导的肿瘤发生
基本信息
- 批准号:10189532
- 负责人:
- 金额:$ 47.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-07-01 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:Adaptive Immune SystemAddressAnimalsB-LymphocytesBALB/cJ MouseBacteriaBiological Response ModifiersBlood-Borne PathogensCD8B1 geneCancer ModelCharacteristicsChicagoDataDevelopmentElementsEnvironmentEnvironmental Risk FactorEpigenetic ProcessEscherichia coliEtiologyEventGene Expression ProfilingGenesGenomeGerm-FreeGnotobioticGoalsHumanImmune responseImmunologic ReceptorsIncidenceInsertional MutagenesisLactobacillusLigandsLiverLymphomaMalignant NeoplasmsMalignant neoplasm of liverMammalian GeneticsMediatingMonitorMurine leukemia virusMusMutationOncogene ActivationOncogenesOralPhenotypeProcessPropertyProto-OncogenesResearchResistanceRetroviridaeRoleSeriesShigellaSomatic MutationSpleenSterilitySystemT cell responseT-LymphocyteTechnologyTestingTimeTumor EscapeUniversitiesUp-RegulationVariantVertebratesViralViral OncogeneVirus Replicationadaptive immune responseanti-cancerbacterial geneticscancer immunotherapycarcinogenesiscell growth regulationcell typecolon cancer progressioncommensal bacteriacommensal microbesgerm free conditiongut microbesgut microbiotainterestleukemialeukemogenesismetabolomicsmicrobialmicrobiotamutantresponsetumortumorigenesisvirology
项目摘要
Abstract
Retroviruses induce a broad range of tumors in vertebrates. Although some retroviruses carry
oncogenes in their genome, the vast majority of retroviruses do not encode such elements and thus, their
capacity to induce tumors depends on integration near cellular proto-oncogenes. However, oncogene
activation alone is not sufficient for tumor induction and additional events are required for tumor development.
Murine Leukemia Virus (MuLV), which can spread as an oral and as a blood-borne pathogen, is highly
proficient in causing leukemia. Intriguingly, tumor incidence within the same strain of infected mice varies
between different facilities. Among environmental factors that may differ between the research labs, the
variation in gut microbiota stands out.Thus, we sought to determine whether the microbiota contributes to
virally-induced leukemogenesis. Accordingly, we monitored virally-induced leukemia in germ-free (GF, sterile)
and specific pathogen free (SPF) conventionally raised BALB/cJ mice. Even though MuLV replication and
spread were not affected in the absence of the microbiota, GF mice were significantly more resistant to the
leukemia than SPF mice. Colonizing GF mice with a defined group of commensal bacteria (Altered Schaedler’s
Flora), or with a single bacterium such as Lactobacillus murinus but not Parabacteroides distasonis or similar
to E. coli and shigella (SECS) did not change virus replication but abolished the tumor-resistant phenotype of
the colonized mice, indicating that some gut microbes have tumor-promoting properties. At the same time, GF
mice lacking adaptive immune system (T and B lymphocytes) developed leukemia at a high rate suggesting
that the gut microbes facilitate leukemia promotion by counteracting the adaptive immune response. Gene-
expression analysis of the pre-leukemic spleens revealed several negative regulators induced by the
microbiota. Among those, the ‘V-set and Ig domain-containing 4’ (VSig4) gene, a known negative regulator of
T-cell responses attracted our interest because it was found upregulated in various human cancers.
The gut microbiota has been implicated in both progression of cancers of colon and liver (‘local’
influence), as well as in systemic anti-cancer effect by enhancing the effect of anti-cancer immunotherapy.
There is also a hint that the microbial environment can influence development of non-virally induced
lymphomas. To identify the mechanism(s) by which the gut microbiota promotes leukemia, we will use our
expertise in virology, mammalian genetics and gnotobiotic technologies (Dr. Golovkina, University of Chicago)
and expertise in bacterial genetics and metabolomics (Dr. Fischbach, Stanford University). The goals of the
proposal are: to determine the role of microbially regulated-VSig4 in virally-induced leukemogenesis; to
characterize the bacterial compound(s) responsible for virally-induced leukemia development; to determine
whether the gut microbiota influences leukemia development in a non-viral model of cancer.
摘要
逆转录病毒可引起脊椎动物的多种肿瘤。尽管一些逆转录病毒携带
在它们的基因组中,绝大多数逆转录病毒不编码这些元件,因此,它们的
诱发肿瘤的能力取决于细胞原癌基因附近的整合。然而,癌基因
单靠激活是不足以诱导肿瘤的,肿瘤的发展还需要额外的事件。
小鼠白血病病毒(MuLV)可作为口腔传播和血液传播的病原体,是高度
精通导致白血病。有趣的是,同一品系感染小鼠的肿瘤发病率各不相同。
在不同的设施之间。在研究实验室之间可能有所不同的环境因素中,
肠道微生物区系的变异尤为突出。因此,我们试图确定微生物区系是否对
病毒诱导的白血病形成。因此,我们监测了病毒诱导的无菌白血病(无菌)。
无特定病原体(SPF)常规饲养的BALB/CJ小鼠。即使MuLV复制和
在没有微生物区系的情况下,扩散不受影响,GF小鼠对
白血病比SPF小鼠。用一组确定的共生细菌(改变的Schaedler‘s)定植GF小鼠
植物),或与单一细菌,如鼠乳杆菌,但不与副杆菌或类似物
对大肠杆菌和志贺氏菌(SECS)的抗药性没有改变病毒的复制,但取消了对肿瘤的抗药性表型
被定植的小鼠,表明一些肠道微生物具有促肿瘤特性。同时,广发
缺乏适应性免疫系统(T和B淋巴细胞)的小鼠患白血病的几率很高
肠道微生物通过对抗适应性免疫反应促进白血病的发生。基因-
对白血病前期脾的表达分析揭示了几种负性调节因子
微生物区系。其中,‘V-set和Ig结构域包含4’基因(VSig4)是一种已知的负性调节因子
T细胞反应引起了我们的兴趣,因为它在各种人类癌症中被发现上调。
肠道微生物区系与结肠癌和肝癌(“局部”)的进展有关
影响),以及通过增强抗癌免疫治疗的效果而在全身抗癌作用方面。
也有迹象表明,微生物环境可以影响非病毒诱导的
淋巴瘤。为了确定肠道微生物区系促进白血病的机制(S),我们将使用我们的
病毒学、哺乳动物遗传学和灵知生物技术方面的专业知识(芝加哥大学Golovina博士)
以及细菌遗传学和代谢组学方面的专业知识(斯坦福大学Fischbach博士)。世界银行的目标是
建议是:确定微生物调控的VSig4在病毒诱导的白血病发生中的作用;
鉴定导致病毒诱导的白血病发生的细菌化合物(S);确定
肠道微生物区系是否影响非病毒性癌症模型中白血病的发展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL ANDREW FISCHBACH其他文献
MICHAEL ANDREW FISCHBACH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL ANDREW FISCHBACH', 18)}}的其他基金
Project 3: Microbiota generated aryl sulfates and secondary bile acids in cardiometabolic disease
项目 3:微生物群在心脏代谢疾病中产生芳基硫酸盐和次级胆汁酸
- 批准号:
10206257 - 财政年份:2019
- 资助金额:
$ 47.69万 - 项目类别:
Project 3: Microbiota generated aryl sulfates and secondary bile acids in cardiometabolic disease
项目 3:微生物群在心脏代谢疾病中产生芳基硫酸盐和次级胆汁酸
- 批准号:
10447071 - 财政年份:2019
- 资助金额:
$ 47.69万 - 项目类别:
Virally-induced tumorigenesis controlled by the microbiota
由微生物群控制的病毒诱导的肿瘤发生
- 批准号:
9751590 - 财政年份:2019
- 资助金额:
$ 47.69万 - 项目类别:
Virally-induced tumorigenesis controlled by the microbiota
由微生物群控制的病毒诱导的肿瘤发生
- 批准号:
10667586 - 财政年份:2019
- 资助金额:
$ 47.69万 - 项目类别:
Virally-induced tumorigenesis controlled by the microbiota
由微生物群控制的病毒诱导的肿瘤发生
- 批准号:
10425354 - 财政年份:2019
- 资助金额:
$ 47.69万 - 项目类别:
Project 3: Microbiota generated aryl sulfates and secondary bile acids in cardiometabolic disease
项目 3:微生物群在心脏代谢疾病中产生芳基硫酸盐和次级胆汁酸
- 批准号:
10653055 - 财政年份:2019
- 资助金额:
$ 47.69万 - 项目类别:
A complete map of the top 100 molecules from the gut microbiome
肠道微生物组前 100 个分子的完整图谱
- 批准号:
9162738 - 财政年份:2016
- 资助金额:
$ 47.69万 - 项目类别:
A complete map of the top 100 molecules from the gut microbiome
肠道微生物组前 100 个分子的完整图谱
- 批准号:
9540375 - 财政年份:2016
- 资助金额:
$ 47.69万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 47.69万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 47.69万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 47.69万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 47.69万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 47.69万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 47.69万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 47.69万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 47.69万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 47.69万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 47.69万 - 项目类别:
Research Grant